|
Administration & Dosage
|
PO,
●Breast cancer:
*Adjuvant, postmenopausal,ER(+), following 2 to 3 years of adjuvant tamoxifen: 25 mg QD after a meal; initiate after 2-3 years of tamoxifen and continue for completion of 5 consecutive years of adjuvant endocrine therapy.
*Advanced, postmenopausal, following progression on tamoxifen therapy: 25 mg QD after a meal.
|
|
Adverse reaction
|
【>10%】Hypertension; fatigue, insomnia, pain, headache, depression; hyperhidrosis, alopecia, dermatitis; hot flash; N/V, abdominal pain; increased Alk-P; arthralgia; dyspnea.
【1-10%】Edema, IHD; dizziness, anxiety; paresthesia, carpal tunnel syndrome, paresthesia; wt gain; diarrhea, anorexia, constipation, increased appetite; UTI; increased Bil; myalgia, osteoarthritis, weakness, osteoporosis, fracture, muscle cramps; visual disturbance; increased SCr; flu-like symptoms, bronchitis, URI; fever.
【<1%】Not referred here, please see package insert or other references.
【Unknown freq.】Chest pain; confusion, hypoesthesia; pruritus, skin rash; increased follicle-stimulating hormone, increased luteinizing hormone, increased sex hormone binding globulin; dyspepsia; lymphedema; infection.
|